

1 **TITLE:** The Female Sexual Function Index: reliability and validity in Spanish
2 postmenopausal women.
3
4

5 **RUNNING TITLE:** Validation of the Spanish FSFI.

6
7 Pérez-Herrezuelo Fidel, MD^a,
8 Hita-Contreras Fidel, MD, PhD^b
9 Martínez-Amat Antonio, PhD^b
10 Aibar-Almazán Agustín, PhD^b
11 Cruz-Díaz David, PhD^b
12 Wangenstein Rosemary, PhD^b
13 Achalandabaso Ochoa Alexander, PhD^b
14 Díaz-Mohedo Esther, PhD^c
15

16 ^a Department of obstetrics and Gynecology. Hospital Universitario Virgen de las Nieves,
17 Granada, Spain.

18 ^b Department of Health Sciences, Faculty of Health Sciences, University of Jaén, Jaén,
19 Spain.

20 ^c Department Physiotherapy, University of Malaga, Malaga, Spain
21

22 **Source(s) of financial support:** None
23

24 **Funding received for this work:** none
25

26 **Conflict of interest:** The authors claim to have no conflict of interest.
27
28
29
30
31
32
33
34
35
36
37

38 **Address correspondence to:**

39 Fidel Hita Contreras.

40 Department of Health Sciences, Faculty of Health Sciences, University of Jaén, E-
41 23071, Jaén, Spain.

42 Tel +34-953-212921, Fax +34-953-012141,

43 E-mail: fhita@ujaen.es
44
45
46
47
48

1 ABSTRACT

2 **Objective:** To examine the reliability and validity of the Spanish version of the Female
3 Sexual Function Index (FSFI) and its ability to discriminate between women with and
4 without female sexual dysfunction (FSD) among Spanish postmenopausal women.

5 **Methods:** A total of 152 postmenopausal women completed the Spanish version of
6 FSFI. Internal consistency, test-retest reliability, and construct validity (exploratory
7 factor analysis) were analyzed. Concurrent and divergent validity were assessed using a
8 visual analogue scale for overall satisfaction with sexual life and the Hospital Anxiety
9 and Depression Scale, respectively. To determine the ability and the accuracy of the
10 FSFI total score in discriminating between women with and without FSD, a receiver
11 operating characteristic (ROC) curve analysis was performed.

12 **Results:** Factor analysis suggested a three-factor structure (explained variance 77.77%).
13 The Spanish FSFI showed substantial-to-excellent test-retest reliability, with good
14 internal consistency in the FSFI total score (Cronbach's alpha=0.964) as well as in its
15 three dimensions. The FSFI total and domains scores showed strong ($r>0.50$) and
16 significant correlations ($p<0.01$) with overall satisfaction with sexual life (concurrent
17 validity), and low correlations with anxiety and depression (divergent validity). The
18 Spanish FSFI total score and dimensions were significantly able to discriminate
19 between women with and without FSD ($p<0.05$), with an optimal cut-off point of
20 <24.95 for the FSFI total score (64.15% sensitivity and 75.76% specificity).

21 **Conclusions:** The Spanish FSFI is a valid and reliable instrument for assessing and
22 discriminating for FSD among Spanish postmenopausal women.
23
24
25

26 **Keywords:** Female sexual function; Postmenopausal; Psychometric; Reliability;
27 Validity.
28
29

30 INTRODUCTION

31 Female sexual dysfunction (FSD) is a multi-causal and a multi-dimensional medical
32 problem that adversely affects self-esteem and quality of life, causing emotional distress
33 and relationship problems.¹ The International Consensus Development Conference on
34 Female Sexual Dysfunction recommends the inclusion of personal distress and
35 interpersonal difficulties as an integral part of FSD². Female Sexual Dysfunction has a
36 major impact on women's quality of life, with effects that reach the social, physical,
37 psychological, domestic, and occupational spheres of life. Epidemiological surveys
38 report a variable prevalence of FSD, ranging from 19% to 45%,³ with 15% of the
39 population reporting a sexual problem that causes significant personal distress.⁴
40 With increased longevity, women spend about one third of their life in the
41 postmenopausal period,⁵ and sexual dysfunction is one of the primary health concerns
42 of postmenopausal women.⁶ The frequency of these sexual problems increases as
43 menopause approaches, and then reaches a peak in the postmenopausal years.⁷ The
44 Women's International Study of Health and Sexuality (WISHeS) of 2006 estimated a
45 prevalence of low sexual desire among postmenopausal women of 9%–26%.⁸ Hormonal
46 changes associated with estrogen may also alter a patient's sexual activity and interest.
47 The menopause-related decline of estrogen levels, together with other sex steroids, is
48 linked to the development of the genitourinary syndrome of menopause.⁹ The main
49 signs and symptoms of the vulvovaginal and lower-urinary tract associated with this

1 condition have a considerable impact on sexual health and quality of life, significantly
2 contributing to sexual dysfunction in postmenopausal women.¹⁰
3 Having access to valid and reliable assessment tools for FSD is important for both
4 research and clinical practice.¹¹ Several methods can be used to evaluate FSD (i.e.
5 photoplethysmography, Doppler velocimetry, or magnetic resonance imaging), but self-
6 reported questionnaires are considered to be the gold standard for measuring FSD in
7 outcome and diagnostic studies of FSD that evaluate sexual function in women. This
8 tool has a level 1 of evidence and a grade A recommendation.¹²
9 The Female Sexual Function Index (FSFI) is a universal and widely used
10 multidimensional questionnaire that evaluates the key dimensions of sexual function in
11 women.¹³ The FSFI consists of 19 items which refer to the past 4 weeks. These items
12 are summarized into 6 domains or subscales: sexual desire (items 1 and 2), arousal
13 (items 3, 4, 5, 6), lubrication (items 7, 8, 9, 10), orgasm (items 11, 12, 13), satisfaction
14 (items 14, 15, 16), and pain (items 17, 18, 19). Subscales range from 0 (or 1) to 5, and
15 the sum of scores for these six subscales yields one global score of female sexual
16 function (with higher scores indicating better sexual function).
17 The FSFI has been validated for several languages and populations,¹⁴⁻¹⁸ and its
18 applicability has been confirmed at various life stages.¹⁹⁻²¹ However, and to the extent
19 of our knowledge, no validation of the FSFI psychometric properties has been carried
20 out for a Spanish postmenopausal population. Thus, the objective of the present study
21 was to evaluate the psychometric properties of the Spanish version of the FSFI in
22 Spanish postmenopausal women by assessing its internal consistency and test-retest
23 reliability, as well as its construct, concurrent, and divergent validity. In addition, we set
24 out to assess the ability of the Spanish version of the FSFI to discriminate between
25 women with and without FSD among a population of Spanish postmenopausal women.

27 **METHODS**

28 **Participants**

29 Out of 323 postmenopausal women who were initially contacted, 152 (ages 49-81
30 years) participated in this study, which took place from July 2018 to October 2018. A
31 flow chart of participants is presented in Figure 1. Participants were recruited by
32 contacting the staff of several associations of postmenopausal women in the Eastern
33 Andalusian region. The sample size of this study was considered appropriate according
34 to psychometric recommendations described by Kline (at least 100 participants).²²
35 Before filling out the questionnaires, all women were interviewed to collect certain
36 demographic data such as age, years since menopause onset, occupational, educational
37 and marital status, and smoking habits.

38 This study was approved by the Ethical Committee of the University of Jaén, Spain. All
39 participants gave their written informed consent to participate in this study, which was
40 conducted in accordance with the Declaration of Helsinki, good clinical practices, and
41 all applicable laws and regulations. Inclusion criteria were: having experienced at least
42 twelve months of amenorrhea, being sexually active in the previous four weeks, capable
43 of completing the questionnaire, and willing to provide their written informed consent
44 to participate in the study. Participants were excluded if they suffered from a chronic
45 and/or severe medical disease, or from any neuropsychiatric disorder that could
46 influence their responses to the questionnaire.

48 **Questionnaires**

49 Following the guidelines recommended by the International Quality of Life Assessment
50 project for cross-cultural translation,²³ the original version of the FSFI was

1 independently translated into Spanish by two bilingual experts working together with
2 clinical professionals who were familiar with both the topic and the research concept.
3 Then, the translators and researchers reached a consensus for a preliminary forward
4 translation and the Spanish version of the FSFI was then completed by 20 participants
5 in order to verify that they were able to understand the instructions, questions, and
6 answering options. The time required to complete the questionnaire was 15-20 minutes.
7 Finally, two bilingual experts translated the Spanish version back into English. A
8 comparison between the initial English and the final English versions showed semantic
9 and linguistic equivalence.

10 To evaluate test-retest reliability, the Spanish FSFI was again completed by 50
11 randomly chosen women two weeks later. The test-retest time interval was long enough
12 for participants to forget how they had previously responded, but sufficiently short that
13 their sexual function outcomes were unlikely to have changed.

14 In order to assess concurrent validity of the Spanish FSFI we employed a visual
15 analogue scale (VAS) to measure overall satisfaction with sexual life (concurrent
16 validity). It consisted of 100-mm lines with descriptors at both ends representing
17 extremes of satisfaction (from not-at-all-satisfied to very-satisfied).²⁴ The Hospital
18 Anxiety and Depression Scale (HADS)²⁵ was used to evaluate discriminant validity.
19 This is a self-administered questionnaire widely used for detecting anxiety and
20 depressive disorders. It comprises 14 items, 7 of which relate to anxiety symptoms and
21 7 to depressive symptoms. The total scores range from 0 to 21 for both depression and
22 anxiety. In this study we used the Spanish version of HADS.²⁶ Two researchers
23 assessed, via a structured clinical interview, the presence of FSD based on the
24 Diagnostic and Statistical Manual of Mental Disorders (**DSM-5**) criteria,²⁵ which
25 include the presence of personal distress or interpersonal difficulties.

26 27 **Statistical analysis**

28 Data management and analysis were performed using the SPSS 20.0 statistical package
29 (SPSS Inc., Chicago, IL, USA). Data were described using mean and standard deviation
30 (SD) for the continuous variables, and frequencies and percentages for the categorical
31 variables. The level of statistical significance was set at $p < 0.05$. Test-retest reliability
32 was determined using Intraclass Correlation Coefficients (ICC_{2,1}) by Shrout and Fleiss.
33 Reliability was considered poor when the ICC was < 0.40 , moderate between 0.40 and
34 0.75, substantial between 0.75 and 0.90, and excellent when $ICC > 0.90$.²⁸

35 Cronbach's α coefficient was used to assess the internal consistency of the instrument.
36 Values ≥ 0.70 were considered acceptable for general research purposes.²⁹ **Given that**
37 **different factor structures have been showed in prior validations^{14,18}, and due to the**
38 **characteristics of the sample population of this study (postmenopausal women), an**
39 **exploratory factor analysis using principal component analysis was performed to test**
40 **construct validity.** A varimax rotation of factors was used, and the Kaiser-Meyer-Olkin
41 (KMO) measure of sampling adequacy was obtained. A KMO value ≥ 0.60 was
42 considered to be acceptable.³⁰ Pearson's correlation coefficient (r) was employed to
43 analyze concurrent validity of the Spanish FSFI with overall satisfaction with sexual life
44 (VAS), as well as divergent validity with anxiety and depression (HADS). Correlation
45 coefficients > 0.50 were considered to be strong, and those between 0.30 and 0.50 were
46 considered to be moderate.³¹

47 Discriminant validity was assessed by comparing the mean scores of the FSD and non-
48 FSD groups using Student's t test. The accuracy of the Spanish FSFI total score in
49 discriminating between participants with and without FSD was evaluated using receiver
50 operating characteristic (ROC) curve analysis. Participants were first diagnosed with

1 FSD according to **DSM-5** criteria, and then a total cut-off point was calculated for the
2 FSFI total score, together with its respective predictive values. In a ROC curve, the true-
3 positive rate (sensitivity) is plotted in the function of the false-positive rate for different
4 cut-off points. Each point on the ROC curve represents a sensitivity/specificity pair
5 corresponding to a particular decision threshold.³² The area under the ROC curve
6 (AUC) was also calculated as a measure of how well a parameter is able to distinguish
7 between two groups (with and without FSD). AUC was considered statistically
8 significant when the 95% CI did not include the 0.5 value. The method of Hanley and
9 McNeil³³ and the binomial exact test were used to calculate the standard error of AUC
10 and the CI for the AUC, respectively.

11 **RESULTS**

12 A total of 152 women completed all the questionnaires included in this study. Their
13 descriptive characteristics are shown in Table 1.

14 The mean age of participants was 63.91±6.99 years. Most of them were non smokers
15 (92.10%), 71.71% were married or living with their partner, 57.24% had either no
16 formal education at all or only primary education, and 63.16% came from urban areas.
17 The mean FSFI total score of the participants was 22.78±7.07.

18 The exploratory factor analysis of the Spanish FSFI (using the principal components
19 option) suggested a three-factor structure (Table 2), in which all items corresponding to
20 original subscales Desire, Arousal and Orgasm, together with items 7 and 9 of
21 Lubrication, were included in one single factor (dimension 1). **Items 14, 15 y 16,**
22 **(original satisfaction subscale) were loaded in another factor (dimension 2), together**
23 **with items 8 (difficulty in becoming lubricated) and 10 (difficulty in maintaining**
24 **lubrication), and finally Items corresponding to pain were loaded in a third different**
25 **factor (dimension 3).** The total variance explained by this model was 77.77%, and
26 sampling adequacy was measured as KMO = 0.921 (p<0.001). For this reason the
27 sample can be considered adequate for the purposes of this analysis.

28 As for reproducibility, the test-retest data of the Spanish version of FSFI show excellent
29 reliability for the total score, dimensions 1 and 2, and items 3, 4, 14, 15, and 16. The
30 rest of the items of the Spanish FSFI show substantial reliability (Table 3). Internal
31 consistency reached good values, with a Cronbach's alpha value of 0.964 for the FSFI
32 total score and 0.964, 0.916, and 0.899 for dimensions 1, 2, and 3, respectively.

33 Domain intercorrelations of the Spanish FSFI were significantly high (all p<0.01) for all
34 dimensions (Table 4). FSFI total score was highly correlated with all dimensions, with
35 Pearson's correlation coefficients of 0.961, 0.911, and 0.679 for dimensions 1, 2, and 3,
36 respectively. To measure concurrent validity (Table 5), the correlations of the Spanish
37 FSFI total score and dimensions with overall satisfaction with sexual life (VAS) were
38 calculated using Pearson's coefficient. Our analysis showed strong (r>0.50) and
39 significant correlations (p<0.01) for all dimensions and also for the total FSFI score. As
40 for divergent validity, we only found low degrees of correlation of the FSFI total score
41 and its domains with anxiety and depression as assessed by the HADS.

42 To evaluate discriminant validity, scores for the FSFI and its dimensions were
43 compared between participants with and without FSD. Statistically significant
44 differences between the two groups were observed for the FSFI total score and for all
45 domains (Table 6). When analyzing the degree of accuracy in discriminating between
46 participants with and without FSD, our results show that total score and all dimensions
47 had a statistically significant AUC (Table 7). For the total score of FSFI, a cut-off point
48 of <24.95 had a 64.15% sensitivity and a 75.76% specificity for detecting FSD (Figure
49 2).
50

DISCUSSION

In the present study we assessed the psychometric properties of the Spanish FSFI in postmenopausal women. The FSFI has been found to be a valid and reliable instrument for assessing female sexual function among this population, and to be able to discriminate between women with and without sexual disorders.

In our analysis, the mean \pm SD score for the FSFI total score was 22.78 \pm 7.07, which is comparable to the score (22.0) described by Carranza-Lira et al.³⁴ in a cross-sectional study performed in postmenopausal women in Mexico (55-59 years). Nevertheless, in other studies such as the one performed in Iranian women (52.8 \pm 3.7 years) the mean FSFI total score was higher (24.11 \pm 6.04).³⁵ These differences may be due to the fact that the mean age of participants in our study was higher. Physical, mental, and emotional changes associated with the aging process have been described to affect sexual function, and their effects add up to those of menopause.³⁵ The time required to complete the Spanish FSFI was between 15 and 20 minutes, while in other validations it was 10-20 minutes (Portuguese),³⁷ or 15 minutes (Chinese).³⁸ Given that there are other factors apart from the questionnaire that may influence the probability of a particular response,³⁹ such as the specific characteristics of persons to whom it is administered, these differences may be linked to the fact that in the present study 57.24% of the participants had primary school education or less, while in other validations 88.4% had secondary education or more (Chinese),³⁸ and 89% had medium-level education or more (Portuguese).³⁷

Exploratory factor analysis by principal components yielded a three-factor structure, with a total explained variance of 77.77% and a KMO value of 0.921. This is larger than 0.60,³⁰ the minimum recommended value considered as adequate for the analysis. The items of the Lubrication domain referring to frequency were integrated with the items of the original domains Desire, Arousal, and Orgasm (dimension 1). In the Polish validation, Nowosielski, et al.⁴⁰ showed that Desire and Arousal were loading in the same factor, as did Ghassamia et al.¹⁸ Moreover, our results revealed that items concerning pain loaded in one single factor (dimension 3), which is in accordance to previous research.^{14,41} Finally, the items of the original Lubrication subscale referring to difficulty were included in the same factor, together with items of the original Satisfaction subscale (dimension 2). This could be related to the characteristics of the participants, the physical and psychological importance linked to lubrication problems, and their association with sexual dysfunction among postmenopausal women.⁴² Our results may be interpreted as an example of how the different domains of female sexual function overlap, and illustrate the multifactorial nature of female sexual dysfunction.⁴³ In order to assess test-retest reliability, the questionnaire was administered again two weeks later to a randomly selected subset of the population, a time period that has been employed before in other FSFI validations.^{44,45} In the original version, overall test-retest reliability coefficients were high for every individual domain.¹³ The ICC values of the Spanish FSFI were substantial-to-excellent for the FSFI total score, with ICC values ranging between 0.884 and 0.972, which are comparable to those described by Takahashi et al.¹⁴ in the analysis of the Japanese version of FSFI.

In the original validation, Rosen et al.¹³ described a high degree of internal consistency, with Cronbach's alpha values of 0.89 and higher, and 0.97 for the FSFI total score. A recent validation of the Persian version (53.63 \pm 7.8 years) reported a Cronbach's alpha larger than 0.80 for the entire scale and its dimensions.⁴⁶ Our analysis showed good reliability values for all the dimensions of the Spanish version (0.899-0.964), higher than those described in the Colombian validation¹⁶ (0.84-0.89) or in the Iranian version

1 of FSFI (0.72-0.90).⁴¹ Meanwhile, our Cronbach's alpha for the FSFI total score was
2 0.964, which is in agreement with the reliability values reported in studies performed in
3 different population sets such as healthy women from Poland aged 17-55 years⁴⁰ or
4 Swedish women with hypoactive sexual desire disorder.⁴⁴

5 The analysis of the intercorrelations between the FSFI total and individual dimensions
6 scores revealed that the weakest intercorrelations were observed for dimension 3 (pain
7 items), which is in agreement with previous validations,^{13,40,47} while the strongest
8 correlations appeared between dimensions 1 and 2 and between FSFI total score and
9 both dimensions 1 and 2. Similar results were described in other studies where the
10 highest correlations appeared between the original domains Desire and Arousal,⁴⁰ (both
11 included in domain 1 of the Spanish FSFI) or between Desire with Arousal, and Orgasm
12 with Arousal and Satisfaction (which is included in domain 2).⁴⁸

13 As regards concurrent validity, we employed a VAS to assess respondents' overall
14 satisfaction with their sex life, which has been previously used in other
15 validations.^{14,40,41} Our results revealed a strong significant correlation ($p < 0.001$)
16 between all the dimensions and the total score of the Spanish FSFI, which indicates a
17 sufficient degree of concurrent validity. These results are in agreement with those
18 reported in the validations of the Japanese,¹⁴ Polish,⁴⁰ and Iranian⁴¹ FSFI versions. As
19 for divergent validity (low association with a test that measures a different domain or
20 entity), the Spanish FSFI total score and dimensions showed very low and non-
21 significant correlations with depression and anxiety as assessed with HADS, in
22 accordance with the findings reported in the Swedish validation (which employed the
23 anxiety and depression subscales of the Symptom Checklist-90-Revised).⁴⁴

24 Finally, in our study 65.13% of the participants had FSD, a similar proportion to the one
25 recently reported by Nazarpour et al.³⁵ (61%, also among postmenopausal women). As
26 for discriminant validity, our results indicate that all the scores yielded significant
27 values in discriminating between participants with and without FSD, with an AUC of
28 0.721 for the Spanish FSFI total score, and with dimension 3 (pain) showing the largest
29 AUCs (0.807). Based on the AUC analysis, we established a cut-off for the Spanish
30 FSFI total score of < 24.95 to discriminate between Spanish postmenopausal women
31 with and without FSD. Higher cut-off points have been proposed in the Polish (27.5)⁴⁰
32 and Greek (26.0)⁴⁷ validations of FSFI, and Wiegel et al.⁴³ described an optimal cut-off
33 score of 26.55 in a study performed in several samples of women with mixed sexual
34 dysfunctions (18-74 years). These differences may be associated with the fact that the
35 participants in our study are, on average, older in age, postmenopausal, and present a
36 lower educational level, factors that have been associated with worsened sexual function
37 and therefore with a lower FSFI total score.^{36,49}

38 Some limitations of the present study should be considered. It was conducted on a
39 convenience sample of participants, and thus the generalizability of its results to the
40 Spanish female population or to other subpopulations might be limited. Also, 36.84% of
41 the participants were from rural areas, 13.82% had university education, and 28.95%
42 had secondary education. Our results are only applicable to the Spanish population,
43 which is why this adaptation should be used with caution in other Spanish-speaking
44 countries. Another limitation of the study is the lack of assessment of partner variables,
45 of the use of hormone replacement therapy (HRT), and of other medications that may
46 affect sexual function (e.g. antidepressants). Future studies should be conducted among
47 a more general population, including women with different health conditions, with a
48 heterogeneous educational level, and from a variety of geographical regions. In
49 addition, future studies should take into account partner variables, as well as usage of
50 HRT and of any medication with the potential to affect sexual function.

1
2 **CONCLUSIONS**

3 The results of the present study reveal that the Spanish version of the FSFI shows good
4 internal consistency and test-retest reliability, as well as good construct, concurrent, and
5 divergent validity for a population of postmenopausal women. Moreover, the Spanish
6 version of FSFI shows satisfactory general psychometric properties, and is able to
7 discriminate between women with and without sexual dysfunctions among a population
8 of Spanish postmenopausal women.

9
10 **REFERENCES**

- 11 1. Addis IB, Van Den Eeden SK, Wassel-Fyr CL, et al. Sexual activity and function in
12 middle-aged and older women. *Obstet Gynecol* 2006;107:755–764.
- 13 2. Basson R, Berman J, Burnett A, et al. Report of the international consensus
14 development conference on female sexual dysfunction: definitions and
15 classifications. *J Urol* 2000;163:888–893.
- 16 3. Hayes RD, Dennerstein L, Bennett CM, Fairley CK. What is the “true” prevalence
17 of female sexual dysfunctions and does the way we assess these conditions have an
18 impact? *J Sex Med* 2008;5:777–787.
- 19 4. Shifren JL, Monz BU, Russo PA, Segreti A, Johannes CB. Sexual problems and
20 distress in United States women: prevalence and correlates. *Obstet Gynecol*
21 2008;112:970-978.
- 22 5. Lejsková M, Alušík S, Suchánek M, Zecová S, Pitha J. Menopause: clustering of
23 metabolic syndrome components and population changes in insulin resistance.
24 *Climacteric* 2011; 14(1):83-91.
- 25 6. Berek, JS. *Berek and Novak’s gynecology*, 14th ed. Philadelphia, PA: Lippincott
26 Williams and Wilkins, 2012.
- 27 7. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States:
28 prevalence and predictors. *JAMA* 1999; 281(6):537-544.
- 29 8. Leiblum SR, Koochaki PE, Rodenberg CA, Barton IP, Rosen RC. Hypoactive
30 sexual desire disorder in postmenopausal women: US results from the Women's
31 International Study of Health and Sexuality (WISHeS). *Menopause* 2006; 13(1):46-
32 56.
- 33 9. Portman DJ, Gass ML. Vulvovaginal Atrophy Terminology Consensus Conference
34 Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal
35 atrophy from the international society for the study of women's sexual health and
36 the North American menopause society. *Climacteric* 2014;17:557–563.
- 37 10. Moral E, Delgado JL, Carmona F, et al. The impact of genitourinary syndrome of
38 menopause on well-being, functioning, and quality of life in postmenopausal
39 women. *Menopause* 2018; 5(12):1418-1423.
- 40 11. Rosen RC. Assessment of female sexual dysfunction: review of validated methods.
41 *Fertil Steril* 2002;77 Suppl 4:S89-93.
- 42 12. Hatzichristou D, Kirana P, Banner L, et al. Diagnostic evaluation of sexual
43 dysfunctions in men and women and the use of symptom scales and questionnaires.
44 *J Sex Med* 2016; 13: 1166–1182.
- 45 13. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): a
46 multidimensional self-report instrument for the assessment of female sexual
47 function. *J Sex Marital Ther* 2000; 26: 191–208.
- 48 14. Takahashi M, Inokuchi T, Watanabe C, Saito T, Kai I. The Female Sexual Function
49 Index (FSFI): development of a Japanese version. *J Sex Med* 2011;8(8):2246-2254.

- 1 15. Filocamo MT, Serati M, Li Marzi V, et al. The Female Sexual Function Index
2 (FSFI): linguistic validation of the Italian version. *J Sex Med* 2014;11(2):447-453.
- 3 16. Vallejo-Medina P, Pérez-Durán C, Saavedra-Roa A. Translation, Adaptation, and
4 Preliminary Validation of the Female Sexual Function Index into Spanish
5 (Colombia). *Arch Sex Behav* 2018;47(3):797-810.
- 6 17. Blümel JE, Binfa L, Cataldo P, et al. Índice de función sexual femenina: un test
7 para evaluar la sexualidad de la mujer. *Rev chil obstet ginecol* 2004;69(2):118-125.
- 8 18. Ghassamia M, Asghari A, Shaeiri MR, Safarinejad MR. Validation of psychometric
9 properties of the Persian version of the Female Sexual Function Index. *Urol J*
10 2013;10(2):878-885.
- 11 19. Chedraui P, Perez-Lopez FR, San Miguel G, Avila C. Assessment of sexuality
12 among middle-aged women using the Female Sexual Function Index. *Climacteric*
13 2009;12:213–221.
- 14 20. Pauls RN, Occhino JA, Dryfhout VL. Effects of pregnancy on female sexual
15 function and body image: A prospective study. *J Sex Med* 2008;5:1915–1922.
- 16 21. Leiblum S, Symonds T, Moore J, Soni P, Steinberg S, Sisson M. A methodology
17 study to develop and validate a screener for hypoactive sexual desire disorder in
18 postmenopausal women. *J Sex Med* 2006;3:455–464.
- 19 22. Kline P. *An Easy Guide to Factor Analysis*. New York: Routledge, 1993.
- 20 23. Bullinger M, Alonso J, Apolone G, et al. Translating health status questionnaires
21 and evaluating their quality: the IQOLA Project approach. International Quality of
22 Life Assessment. *J Clin Epidemiol* 1998;51(11):913-923.
- 23 24. Wewers ME, Lowe NK. A critical review of visual analogue scales in the
24 measurement of clinical phenomena. *Res Nurs Health* 1990;13:227–236.
- 25 25. Zigmond AS, Snaith PR. The hospital anxiety and depression Scale. *Acta Psychiatr*
26 *Scand* 1983.67(6):361–370.
- 27 26. Herrero MJ, Blanch J, Peri JM, De Pablo J, Pintor L, Bulbena A. validation study
28 of the hospital anxiety and depression scale (HADS) in a Spanish population. *Gen*
29 *Hosp Psychiatry* 2003;25(4):277–283.
- 30 27. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental*
31 *Disorders: DSM-5*. 5th ed. Washington, DC: American Psychiatric Publishing,
32 2013.
- 33 28. Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability.
34 *Psychol Bull* 1979;86:420–428.
- 35 29. Cronbach LJ. Coefficient alpha and the internal structure of tests. *Psychometrika*.
36 1951;16:297–334.
- 37 30. Hair JF, Black WC, Babin BJ, Anderson RE. *Multivariate data analysis*. 7th ed.
38 New Jersey: Prentice Hall, 2010.
- 39 31. Cohen J. *Statistical Power Analyses for the Behavioral Sciences*. 2nd ed. Hillsdale,
40 NJ: Lawrence Erlbaum Associates, 1988.
- 41 32. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a
42 fundamental evaluation tool in clinical medicine. *Clin Chem* 1993;39:561-577.
- 43 33. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating
44 characteristic curves derived from the same cases. *Radiology* 1983;148:839-843.
- 45 34. Carranza-Lira S, Núñez FDC. Sexual dysfunction prevalence in a group of pre- and
46 postmenopausal Mexican women. *Prz Menopausalny* 2018;17(1):39-42.
- 47 35. Nazarpour S, Simbar M, Ramezani Tehrani F, Alavi Majd H. Quality of life and
48 sexual function in postmenopausal women. *J Women Aging* 2018;30(4):299-309.
- 49 36. Dennerstein L, Hayes RD. Confronting the challenges: epidemiological study of
50 female sexual dysfunction and the menopause. *J Sex Med* 2005;2:118-132.

- 1 37. Thiel Rdo R, Dambros M, Palma PC, Thiel M, Riccetto CL, Ramos Mde F.
2 Translation into Portuguese, cross-national adaptation and validation of the Female
3 Sexual Function Index. *Rev Bras Ginecol Obstet* 2008;30(10):504-510.
- 4 38. Sun X, Li C, Jin L, Fan Y, Wang D. Development and validation of Chinese
5 version of female sexual function index in a Chinese population-a pilot study. *J Sex
6 Med* 2011;8(4):1101-1111.
- 7 39. Hays RD, Morales LS, Reise SP. Item response theory and health outcomes
8 measurement in the 21st century. *Med Care* 2000;38(9 Suppl):II28-42.
- 9 40. Nowosielski K, Wróbel B, Sioma-Markowska U, Poręba R. Development and
10 validation of the Polish version of the Female Sexual Function Index in the Polish
11 population of females. *J Sex Med* 2013;10(2):386-395.
- 12 41. Fakhri A, Pakpour AH, Burri A, Morshedi H, Zeidi IM. The Female Sexual
13 Function Index: translation and validation of an Iranian version. *J Sex Med*
14 2012;9(2):514-523.
- 15 42. Lo SS, Kok WM. Sexuality of Chinese women around menopause. *Maturitas*
16 2013;74:190-195.
- 17 43. Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-
18 validation and development of clinical cutoff scores. *J Sex Marital Ther* 2005;31:1-
19 20.
- 20 44. Ryding EL, Blom C. Validation of the Swedish version of the Female Sexual
21 Function Index (FSFI) in women with hypoactive sexual desire disorder. *J Sex Med*
22 2015;12(2):341-349.
- 23 45. Wylomanski S, Bouquin R, Philippe HJ, et al. Psychometric properties of the
24 French Female Sexual Function Index (FSFI). *Qual Life Res* 2014;23(7):2079-
25 2087.
- 26 46. Babakhanian M, Ghazanfarpour M, Najafi MN, et al. Psychometric properties of
27 Persian language version of the Female Sexual Function Index (P-FSFI) among
28 postmenopausal women. *J Turk Ger Gynecol Assoc.* 2018;19(4):187-192.
- 29 47. Zachariou A, Filiponi M, Kirana PS. Translation and validation of the Greek
30 version of the female sexual function index questionnaire. *Int J Impot Res*
31 2017;29(4):171-174.
- 32 48. Sidi H, Abdullah N, Puteh SE, Midin M. The Female Sexual Function Index
33 (FSFI): validation of the Malay version. *J Sex Med* 2007;4(6):1642-1654.
- 34 49. Ghazanfarpour M, Khadivzadeh T, Babakhanian M. Investigating the Relationship
35 Between Sexual Function and Quality of Life in Menopausal Women. *J Family
36 Reprod Health* 2016;10(4):191-197.

37
38
39
40
41
42
43
44
45
46
47
48
49
50

Figure 1. Flow diagram of the study participants.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

- 1 Figure 2. The ROC curve of the FSFI total score for discriminating among women with
- 2 and without FSD. ROC: receiver-operating characteristic. FSFI: female sexual function
- 3 index. FSD: female sexual dysfunctions.
- 4
- 5